683 Capital Management LLC Increases Stock Holdings in Aldeyra Therapeutics, Inc. $ALDX

683 Capital Management LLC increased its holdings in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) by 86.6% in the fourth quarter, Holdings Channel.com reports. The firm owned 1,530,000 shares of the biotechnology company’s stock after purchasing an additional 710,000 shares during the period. 683 Capital Management LLC’s holdings in Aldeyra Therapeutics were worth $7,925,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in ALDX. Vanguard Group Inc. grew its position in Aldeyra Therapeutics by 2.6% during the third quarter. Vanguard Group Inc. now owns 3,591,869 shares of the biotechnology company’s stock valued at $18,750,000 after acquiring an additional 90,276 shares during the period. AQR Capital Management LLC grew its position in Aldeyra Therapeutics by 275.4% during the second quarter. AQR Capital Management LLC now owns 1,473,812 shares of the biotechnology company’s stock valued at $5,645,000 after acquiring an additional 1,081,257 shares during the period. Kennedy Capital Management LLC grew its position in Aldeyra Therapeutics by 12.9% during the fourth quarter. Kennedy Capital Management LLC now owns 1,255,838 shares of the biotechnology company’s stock valued at $6,505,000 after acquiring an additional 143,625 shares during the period. Geode Capital Management LLC grew its position in Aldeyra Therapeutics by 0.8% during the second quarter. Geode Capital Management LLC now owns 1,146,597 shares of the biotechnology company’s stock valued at $4,392,000 after acquiring an additional 8,769 shares during the period. Finally, Jacobs Levy Equity Management Inc. grew its position in Aldeyra Therapeutics by 2.2% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 968,751 shares of the biotechnology company’s stock valued at $5,018,000 after acquiring an additional 21,200 shares during the period. Hedge funds and other institutional investors own 59.71% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ALDX. HC Wainwright reissued a “neutral” rating and set a $2.00 price target (down from $10.00) on shares of Aldeyra Therapeutics in a research report on Wednesday, March 18th. Wall Street Zen raised Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. BTIG Research reissued a “buy” rating on shares of Aldeyra Therapeutics in a research report on Tuesday, March 17th. Finally, Weiss Ratings cut Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 20th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $5.50.

Insider Activity at Aldeyra Therapeutics

In related news, CEO Todd C. Brady acquired 250,000 shares of Aldeyra Therapeutics stock in a transaction on Wednesday, June 3rd. The shares were bought at an average price of $1.67 per share, for a total transaction of $417,500.00. Following the completion of the purchase, the chief executive officer directly owned 1,721,298 shares in the company, valued at $2,874,567.66. This trade represents a 16.99% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 11.80% of the stock is currently owned by corporate insiders.

Aldeyra Therapeutics Price Performance

Shares of ALDX opened at $1.83 on Thursday. The stock’s 50-day moving average is $1.69 and its two-hundred day moving average is $3.48. The stock has a market cap of $110.39 million, a PE ratio of -3.98 and a beta of 1.19. Aldeyra Therapeutics, Inc. has a 12 month low of $1.07 and a 12 month high of $6.18.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.07. On average, research analysts anticipate that Aldeyra Therapeutics, Inc. will post -0.43 earnings per share for the current year.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.